Reportable Segment Information (Tables)

12 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Segment Revenue, Operating (Loss) Income and Depreciation and Amortization

Segment revenue, operating income (loss), and depreciation and amortization were as follows:

	Fiscal Year
(In thousands)	2023			2022			2021
Revenue:
Medical Device	$	105,783		$	72,389		$	78,253
In Vitro Diagnostics		26,801			27,562			26,883
Total revenue	$	132,584		$	99,951		$	105,136
Operating income (loss):
Medical Device	$	5,084		$	(22,923	)	$	4,683
In Vitro Diagnostics		12,637			13,073			13,770
Total segment operating income (loss)		17,721			(9,850	)		18,453
Corporate		(12,571	)		(12,247	)		(11,750	)
Total operating income (loss)	$	5,150		$	(22,097	)	$	6,703
Depreciation and amortization:
Medical Device	$	7,874		$	8,368		$	7,224
In Vitro Diagnostics		321			355			395
Corporate		327			419			398
Total depreciation and amortization	$	8,522		$	9,142		$	8,017

Geographic Revenue and Long-lived Assets

Long-lived assets by country, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, were as follows:

	September 30,
(In thousands)	2023		2022
U.S.	$	23,525	$	24,788
Ireland		28,707		30,505